Last updated: June 7, 2026

Executive summary: ACTIFED is a legacy, non-prescription combination cold/allergy drug (decongestant plus antihistamine) with revenue that tracks seasonal respiratory demand, retail price inflation, and competitive substitution by newer OTC lineups and generics across key geographies. Its financial trajectory is structurally constrained by mature, non-proprietary active ingredients, periodic package and label refreshes, and shifting retailer and payer preferences toward streamlined OTC portfolios. The market behaves like a high-volume, low-differentiation OTC category where share gains are usually logistics and merchandising driven rather than sustained product innovation.

What is ACTIFED and what drug actives does it combine?

ACTIFED is marketed as an OTC cold/allergy medicine using a decongestant plus an antihistamine core. Across markets, the brand’s exact formulation (salt forms, dosing, and whether it is “ACTIFED Day” or “ACTIFED Night”) changes by country and regulatory authorization.

Which formulations exist by dosing and day/night use?

Typical OTC pattern for ACTIFED variants includes:

“Day” product: usually daytime dosing with less sedating antihistamine profile
“Night” product: sedating antihistamine antihistamine profile intended for nighttime symptoms
Tablet or capsule dosage forms (varies by country)
Syrup formulations in some markets (varies by country)

How does the combination design drive consumer usage?

Combination products capture multiple symptom buckets in one purchase, but they face substitution pressure from:

single-ingredient decongestants plus antihistamines sold as separate items,
private-label equivalents,
category-specific formulations (sinus-focused, “non-drowsy” variants),
and pharmacy-led switching to higher-margin or better-placed SKUs.

How does the ACTIFED market size move with seasonality and respiratory cycles?

ACTIFED demand is seasonal and event-driven.

Seasonality: Cold and flu season drives spikes in units sold. Allergy season drives secondary demand in warmer months, depending on geography.
Viral intensity and severity: Increased respiratory illness incidence lifts OTC purchasing, including cough/cold combinations.
Weather patterns: Temperature swings and humidity shifts can shift allergy symptom calendars and increase repeat purchasing.

What is the practical market dynamic for an OTC decongestant/antihistamine?

Rapid replenishment: Consumers buy short-course symptom relief, usually within weeks of first onset.
High SKU substitutability: Brand loyalty is weaker than for prescription specialty medicines.
Shelf placement and pharmacy switching: Retailers and wholesalers can rotate inventory and promote alternatives, which affects share at the margin.
Promotional cadence: Seasonal promotions can temporarily lift sell-through but do not protect against longer-term substitution.

What are the key drivers of ACTIFED pricing and margin structure?

ACTIFED is exposed to OTC pricing mechanics rather than prescription reimbursement.

Wholesale and retail markups: Margin is influenced by channel mix (independent pharmacy, chain pharmacy, mass retail).
Promotions and trade spend: Seasonal promotions compress net price and shift margin between manufacturer, distributor, and retailer.
Input costs: Packaging, tablet/capsule excipients, and labor affect cost of goods, but competitive pressure limits pricing power.
Regulatory labeling constraints: Decongestant and antihistamine components can face tighter consumer warnings, which can slow category expansions and increase compliance costs.

What drives net revenue versus gross revenue for OTC brands like ACTIFED?

Net price changes tied to promotions and retailer contracting
Private label competition that caps pricing
Mix shift between day/night, tablet vs syrup, and pack-size variants

How many competitors does ACTIFED face and where is share most contested?

ACTIFED competes within the broader OTC cold and allergy shelf, typically against:

branded combination cold meds,
generics and private-label combination equivalents,
non-drowsy antihistamine decongestant combinations,
single-ingredient alternatives.

What is the competitive pattern in mature OTC combination categories?

Shelf-level substitution: When consumers switch, they often remain in the same symptom class, not move to another therapeutic category.
Brand refresh cycles: Companies update packaging, compress dosing instructions, and reposition as “non-drowsy” or “fast relief,” when allowed.
Channel bundling: Retailers can build “cold season” bundles and promote one or two preferred manufacturers.

When does ACTIFED lose exclusivity or where do exclusivity barriers stop mattering?

For OTC combination brands with legacy active ingredients, exclusivity typically matters early and weakens over time due to genericization and manufacturing pathway learning. The practical constraint for ACTIFED is not patent expiry alone, but the category’s continued generic availability.

What is the main “time-to-generic” risk for ACTIFED-like OTC products?

When active ingredients and core dosage forms are off patent or when formulation/packaging patents are not enforceable long-term, generic and private-label competition increases quickly.
Even if one component is still protected, combination equivalents can enter depending on regulatory permission and existing approvals in each market.

What does the Orange Book status of ACTIFED show in the US?

ACTIFED is commonly marketed as an OTC product. In the US, OTC drug product listing and exclusivity do not map cleanly to the FDA Orange Book regime used for prescription exclusivity and approved application-based patent listings. Without a confirmed US NDA/NADA with Orange Book patent listings for ACTIFED’s specific OTC NDA product number, Orange Book status is not reliably stated from brand name alone.

What Paragraph IV challenges matter for ACTIFED?

Paragraph IV litigation is an FDA Hatch-Waxman construct tied to ANDAs for generic drugs and listed patents in the Orange Book. Because ACTIFED is an OTC brand and is frequently formulation- and market-specific, Paragraph IV challenges cannot be asserted without a verified US application-to-brand mapping and listed patents.

What patent estate protects ACTIFED and how strong is it?

ACTIFED’s defense usually sits in a mix of:

combination formulation claims (if still protected),
specific dosage form claims (tablets, extended-release vs immediate release, if any),
and sometimes process claims,
plus trademark and trade dress protection rather than long-duration molecule exclusivity.

How do formulation and method claims change the competitive landscape?

Strong formulation patents can delay generic equivalents with the same actives and dosing.
Process patents matter only to the extent manufacturing steps are specific and enforceable.
Over time, combination products tend to see erosion as equivalents develop and as patents expire.

How does ACTIFED compare with other OTC cold/allergy combination products on market dynamics?

ACTIFED behaves like a “category incumbent” OTC brand:

it benefits from consumer recognition,
but it is structurally vulnerable to private-label and generic combination substitutes,
and it lacks the compounding demand growth typical of branded prescription franchises.

Where competitive advantages usually come from in this category

distribution depth and retailer agreements,
packaging that reduces consumer confusion (day vs night),
consistent supply during peak season,
and consumer habit formation after repeated seasonal use.

What FDA regulatory path affects ACTIFED’s launches and reformulations?

OTC products typically move through:

NDA or supplement pathways if they are FDA-approved drug products (depending on product history),
labeling updates via OTC monograph changes or approvals,
and reformulations via supplements where permitted.

What regulatory friction can shift ACTIFED’s financials?

label changes and consumer safety wording updates can require reprint cycles and inventory disposal costs,
formulation changes can require additional stability or bioequivalence work depending on the direction of changes,
supply chain disruptions can create stockouts, which permanently reduce shelf share before the next season.

What is ACTIFED’s financial trajectory by year and what patterns are typical?

A mature OTC seasonal brand typically shows:

Unit peaks in Q1 through Q4 depending on hemisphere and climate,
stable baseline demand with periodic promotions,
revenue volatility in off-seasons driven by promotional strategy rather than clinical seasonality,
and margin drift as private label increases.

However, a precise year-by-year financial trajectory for ACTIFED requires verified company financial reporting tied to the specific brand, SKU list, and geography. Without mapping to the exact corporate product segment reporting and the brand’s market-specific revenue attribution, a quantitative trajectory cannot be stated.

How do distribution and channel strategy change ACTIFED’s revenue exposure?

OTC brands are sensitive to channel mix:

pharmacy channels often provide stable repeat exposure,
mass retail can drive volume but increases price pressure,
e-commerce affects promotional intensity and can accelerate substitution.

What operational metrics typically correlate with brand performance

in-stock rate during peak months
SKU availability and shelf facings
promotional participation and discount depth
return rates for overstock after season ends

Which litigation or recalls can affect ACTIFED’s financials?

OTC products can experience reputational and financial impact from:

quality system failures leading to recalls,
mislabeling events,
and adverse event reporting spikes.

But specific litigation and recall events for ACTIFED require verified docket and enforcement records tied to the exact product identifiers.

What generic entry risks exist for ACTIFED in key markets?

Generic entry risk is highest when:

core actives are off patent,
combination packaging does not create enforceable formulation barriers,
and the market supports multiple dosage strengths and day/night formats that generic manufacturers can mirror.

Where are generic alternatives most likely to take share?

the most common dosage strength and pack size,
the channel where private-label penetration is highest,
and the season where promotions force price competition.

How do manufacturing and IP barriers influence ACTIFED’s ability to defend share?

For a mature OTC combination:

manufacturing barrier is usually more about scale and consistent compliance than about bespoke IP,
IP barriers, if any, are narrow and often limited to specific formulation features, which may be engineered around by alternative release profiles or excipient systems.

What does this mean for competitive tactics?

Competitors can wait for patent expiry, then enter with close equivalents.
If formulation patents exist, entrants may pursue “design-around” routes to achieve similar symptom relief with different release mechanics or excipient stacks.

ACTIFED Key Takeaways

ACTIFED’s market dynamics are driven by OTC seasonal demand for cold and allergy symptom relief and by retailer promotional intensity.
Financial trajectory is typically characterized by seasonal volume spikes, pricing compression from private label and generics, and margin drift rather than sustained innovation premium.
Patent and Orange Book driven exclusivity concepts often matter less for legacy OTC combination brands once generics and equivalents are established, and enforcement depends on narrow formulation or dosage-form claims rather than long molecule protection.
The most determinative financial levers are distribution depth, in-stock performance during peak season, and net price discipline amid high substitution.

FAQs

How does the day vs night ACTIFED formulation affect consumer switching and sales seasonality?
What retail channels typically account for the highest ACTIFED share gains during cold season promotions?
When competitors introduce private-label ACTIFED equivalents, how quickly does category-level price compression occur?
Do formulation changes to ACTIFED trigger bioequivalence or stability burdens that delay new strength launches?
Which regulatory label updates for OTC decongestant/antihistamine combinations most often force reprints and affect Q4 availability?

References

FDA Orange Book. FDA. (accessed via FDA Orange Book database).
FDA, Hatch-Waxman Act background materials and ANDA approval framework. FDA.
FDA OTC drug regulations and labeling guidance. FDA.

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	4
Patent Applications:	8
DailyMed Link:	ACTIFED at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ACTIFED	pseudoephedrine hydrochloride; triprolidine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	018996-001	Jun 17, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline	ACTIFED W/ CODEINE	codeine phosphate; pseudoephedrine hydrochloride; triprolidine hydrochloride	SYRUP;ORAL	012575-003	Apr 4, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

ACTIFED Drug Patent Profile

When do Actifed patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for ACTIFED

US Patents and Regulatory Information for ACTIFED

ACTIFED (Decongestant/Antihistamine Combination) Market Dynamics and Financial Trajectory